Praxis Precision Medicines, Inc. Common Stock (PRAX) Stock
Key stats
- Market cap
- $7.33B
- Price / Earnings ratio
- -23.4x
- EPS (TTM)
- -$12.94
- Volume
- Loading
- 52-week high
- $392.70
- 52-week low
- $154.45
Source: third-party data provider, as of November 7, 2026
Compare with PRAX
Recent news

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
PRAX

Praxis Precision Medicines Q2 Earnings Call Highlights
Praxis Precision Medicines Q2 Earnings Call Highlights
PRAX

These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months
These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months
PRAX

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme
PRAX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.69
- MACD 12/26/9
- -2.68
- EMA 9 of MACD
- -6.11
- MACD histogram
- 3.43
- SMA 50
- $293.54
- Price below SMA 50
- EMA 50
- $287.87
- Price below EMA 50
- SMA 200
- $314.09
- Price below SMA 200
- EMA 200
- $296.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
PRAX

Praxis Precision Medicines Q2 Earnings Call Highlights
Praxis Precision Medicines Q2 Earnings Call Highlights
PRAX

These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months
These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months
PRAX

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme
PRAX

The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive
The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive
PRAX

PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates
PRAX

Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study
Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study
PRAX

Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines Q1 Earnings Call Highlights
PRAX

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout
Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout
PRAX

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
PRAX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Praxis Precision Medicines, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Marcio Silva De'Souza M.B.A. | President, CEO & Director | 1979 |
| Mr. Timothy Edwin Kelly | CFO & Treasurer | 1973 |
| Ms. Megan T. Sniecinski | Chief Operating Officer | 1981 |
| Mr. Alex Nemiroff J.D. | General Counsel & Secretary | 1979 |
| Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder and President of Research & Development | — |
| Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer | — |
| Ms. Kelly McCue | Chief People Officer | — |
| Ms. Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | 1975 |
| Mr. Brian Spar | Chief of Staff | — |
| Dr. Orrin Devinsky M.D., Ph.D. | Head of Clinical Strategy | 1958 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 43.69
- MACD 12/26/9
- -2.68
- EMA 9 of MACD
- -6.11
- MACD histogram
- 3.43
- SMA 50
- $293.54
- Price below SMA 50
- EMA 50
- $287.87
- Price below EMA 50
- SMA 200
- $314.09
- Price below SMA 200
- EMA 200
- $296.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $362.00
- Average
- $672.57
- High
- $1,201.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -22.7 | +14.9 | ||||||||||
| 2022 | -26.8 | -10.2 | -21.9 | -24.3 | -5.7 | -69.7 | +40.6 | -3.4 | -30.2 | -14.7 | +8.9 | +9.2 |
| 2023 | +93.8 | -37.3 | -73.3 | +22.3 | -23.2 | +31.1 | -13.9 | +53.4 | +8.9 | -38.3 | +26.7 | +26.9 |
| 2024 | +108.8 | +7.0 | +23.2 | -6.4 | -14.0 | -12.1 | +40.1 | -6.7 | +3.9 | +21.9 | +17.3 | -1.2 |
| 2025 | -3.7 | -51.9 | +12.9 | +4.9 | +1.3 | +5.6 | +25.6 | -15.8 | +17.9 | +274.9 | +8.0 | +59.7 |
| 2026 | +9.6 | +8.9 | -2.5 | -0.1 | +7.9 | -0.1 | -3.7 | +14.7 | -17.6 | -0.3 | -4.2 |



